Celularity Inc
For the period ended Jun 30, 2025. Filed Aug 29, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 29, 2025
CELU$0.71-6.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
Condensed Consolidated Statements of Cash Flows (Unaudited)
(in thousands)
| Six Months Ended June 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flow from operating activities: | ||
| Net loss | $(44,278) | $(28,501) |
| Adjustments to reconcile net loss to net cash used in operations: | ||
| Depreciation and amortization | 3,668 | 4,152 |
| Non cash lease expense | 61 | 87 |
| Provision for credit losses | (53) | 306 |
| Provision for inventory obsolescence | (37) | (50) |
| Change in fair value of warrant liabilities | 1,034 | 1,870 |
| Loss on issuance of common stock to Yorkville in connection with the Side Letter | 382 | — |
| Loss on issuance of common stock in connection with the settlement of debt | 72 | — |
| Issuance of warrants for services | 317 | — |
| Stock-based compensation expense | 5,085 | 5,956 |
| Issuance of common stock to Palantir as consideration for settlement agreement | — | 175 |
| Issuance of common stock relating to Yorkville for debt extension and SEPA commitment fee | — | 317 |
| Issuance of common stock as compensation expense for consulting services | 108 | — |
| Loss on extinguishment of debt | 5,736 | 3,908 |
| Change in fair value of debt | 1,087 | (14) |
| Non cash interest expense | 3,782 | 2,310 |
| Other, net | — | (286) |
| Changes in assets and liabilities: | ||
| Accounts receivable | 2,458 | (3,732) |
| Inventory | 6,214 | 5,150 |
| Prepaid expenses and other assets | 47 | 850 |
| Accounts payable | 1,104 | (397) |
| Accrued expenses and other liabilities | 8,935 | 3,159 |
| Accrued R&D software | — | (3,500) |
| Lease liabilities - operating | 169 | 179 |
| Deferred revenue | 117 | 210 |
| Net cash used in operating activities | (3,992) | (7,851) |
| Cash flow from investing activities: | ||
| Capital expenditures | — | (70) |
| Proceeds from Sanuwave convertible note receivable | — | 2,175 |
| Net cash provided by investing activities | — | 2,105 |
| Cash flow from financing activities: | ||
| Proceeds from warrants and short-term debt - related parties | — | 15,000 |
| Proceeds from the issuance of common stock to Dragasac as consideration for inducement agreement | 2,460 | — |
| Repayments of short-term debt - unaffiliated | — | (17,374) |
| Proceeds from issuance of short-term debt - unaffiliated | — | 2,993 |
| Payment of SEPA commitment fee | — | (25) |
| Proceeds from merchant cash receivable | 891 | — |
| Repayment of merchant cash advance | (221) | |
| Repayments of short-term debt - related parties | (77) | (100) |
| Tax withholding on vesting of restricted stock units | (112) | — |
| Proceeds from PIPE Offering, net of offering costs | — | 6,000 |
| Proceeds from the sale of common stock in PIPE Offering | 1,010 | — |
| Tax withholding on vesting of restricted stock units | — | (357) |
| Net cash provided by financing activities | 3,951 | 6,137 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | (41) | 391 |
| Cash, cash equivalents and restricted cash at beginning of period | 10,977 | 10,163 |
| Cash, cash equivalents and restricted cash at end of period | $10,936 | $10,554 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest | $— | $144 |
| Supplemental non-cash investing and financing activities: | ||
| Property and equipment included in accounts payable and accrued expenses | $— | $(21) |
| Change in fair value of contingent consideration | $650 | $— |
| Issuance of common stock in connection with note payable conversion | $922 | $— |
| Reclassification of warrants from liability classified to equity classified | $501 | $— |
| Deemed dividend relating to inducement of Dragasac warrants | $64 | $— |
| Modification of C.V. Starr warrants in connection with forbearance | $— | $51 |
| Issuance of RWI warrants in connection with forbearance | $— | $1,162 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.